SKU: I031  / 
    CAS Number: 220127-57-1

    Imatinib Mesylate

    ฿2,693.10 - ฿7,506.30
    Imatinib Mesylate

    Imatinib Mesylate is a tyrosine kinase inhibitor used primarily in cancer research primary for leukemia studies. Chronic Myeloid Leukemia (CML) cells contain a hybrid tyrosine kinase BCR/ABL that works to provide the cancer cell with ATP at an uncontrolled rate.  Imatinib Mesylate inhibits this protein to slow cell growth and promote apoptosis.

    Imatinib was invented in the early 1990s by scientists at Ciba-Geigy (which later merged with Sandoz) in 1996 to become Novartis.

    Imatinib is a small molecule inhibitor targeting multiple tyrosine kinases. 

    Mechanism of Action

    Imatinib Mesylate binds to the ATP binding site of the BCR/ABL tyrosine kinase.  This enzyme is the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukemia (CML).
    Molecular Formula C29H31N7O•CH3SO3H
    References

    Goldman JM and Melo JV (2003)  Chronic myeloid leukemia — Advances in biology and new approaches to treatment. New England J. of Med. 349(15):1451-1464

    Marcucci B, Perrotti D, Caligiuri MA (2003)  Understanding the molecular basis of Imatinib Mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Clin. Cancer Res. 9(4):1248-1252

    Mohamed AN, Pemberton P, Zonder J, Schiffer CA. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin Cancer Res. 2003 Apr;9(4):1333-7. PMID: 12684401.